Naomi Eichenbaum | Vice President-Investor Relations |
Eric Dube | Chief Executive Officer |
Jula Inrig | Chief Medical Officer |
Peter Heerma | Chief Commercial Officer |
Chris Cline | Chief Financial Officer |
Bill Rote | Senior Vice President of Research & Development |
Malcolm Kuno | JPMorgan |
Tyler Van Buren | TD Cowen |
Greg Harrison | Bank of America |
Joseph Schwartz | Leerink Partners |
Maurice Raycroft | Jefferies |
Tim Lugo | William Blair |
Vamil Divan | Guggenheim Securities |
Laura Chico | Wedbush Securities |
Alex Thompson | Stifel |
Ed Arce | H.C. Wainright |
Good day, and welcome to the Travere Therapeutics Second Quarter 2023 Financial Results and Corporate Update Conference Call. Today's conference call is being recorded.
At this time, I would like to turn the conference call over to the Vice President of Investor Relations, Naomi Eichenbaum. Please go ahead, Naomi.
Thank you.